TI
GNMK

tru Independence’s GenMark Diagnostics, Inc GNMK Stock Holding History

tru Independence’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-376
Closed -$5 – 938
2020
Q2 		$5 Buy
+376
New +$3.82K ﹤0.01% 714

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

tru Independence's GNMK Position: Q3 2020 in Review

tru Independence sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2020, closing a stake of 376 shares — an estimated $5 sold.

tru Independence first reported a position in GNMK in Q2 2020 and held it in 1 quarter. The position peaked at $5 in Q2 2020. 163 funds tracked by Wall St. Rank hold GNMK as of Q3 2020.

  • tru Independence reported no remaining GenMark Diagnostics, Inc position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 376 GenMark Diagnostics, Inc shares in Q3 2020, an estimated $5.
  • tru Independence first reported a position in GenMark Diagnostics, Inc in Q2 2020 and held it in 1 quarter.
  • tru Independence's GenMark Diagnostics, Inc position peaked at $5 in Q2 2020.
  • 163 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.